Edition:
United States

Biosynex SA (ALBIO.PA)

ALBIO.PA on Paris Stock Exchange

2.46EUR
5:22am EST
Change (% chg)

€0.05 (+2.07%)
Prev Close
€2.41
Open
€2.41
Day's High
€2.46
Day's Low
€2.41
Volume
3,713
Avg. Vol
1,316
52-wk High
€3.21
52-wk Low
€2.11

ALBIO.PA

Chart for ALBIO.PA

About

Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings.... (more)
No analyst recommendations are available for ALBIO.PA.

Overall

Beta: 1.59
Market Cap(Mil.): €17.73
Shares Outstanding(Mil.): 6.18
Dividend: --
Yield (%): --

Financials

  ALBIO.PA Industry Sector
P/E (TTM): -- 32.25 29.87
EPS (TTM): -0.15 -- --
ROI: -4.04 13.46 14.95
ROE: -4.25 17.16 16.29

BRIEF-Biosynex launches capital increase for maximum amount of 3.39 million euros

* Launches a capital increase guaranteed by the founding shareholders with preferential subscription rights for a maximum amount of 3.39 million euros ($3.60 million)

Nov 29 2016

BRIEF-Biosynex H1 operating loss widens to 0.5 mln euros

* H1 operating loss is 500,000 euros ($545,100) versus loss of 101,000 euros a year ago

Oct 27 2016

BRIEF-Biosynex H1 revenue up at 13.3 million euros

* H1 revenue 13.3 million euros ($14.72 million) versus 10.7 million euros year ago Source text for Eikon: Further company coverage: ($1 = 0.9036 euros) (Gdynia Newsroom)

Jul 28 2016

BRIEF-Biosynex awarded 1 mln euro innovation loan by Bpifrance

* Awarded European Investment Fund innovation loan by Bpifrance to finance deployment of its product

Jul 18 2016

BRIEF-Biosynex finalizes 2 acquisitions

* Finalizes 2 acquisitions which should generate additional annual revenue of 12 million euros ($13.4 million)

Jul 05 2016

Earnings vs. Estimates